Efficacy of an early administration of L0013CP 10 MG/DAY versus placebo during 4 weeks in the treatment of infectious diseases induced arthritis painful symptoms. A multicenter, randomised, double-blind, placebo controlled clinical trial in adult pa
Efficacy of an early administration of L0013CP 10 MG/DAY versus placebo during 4 weeks in the treatment of infectious diseases induced arthritis painful symptoms. A multicenter, randomised, double-blind, placebo controlled clinical trial in adult pa
Efficacy of an early administration of L0013CP 10 MG/DAY versus placebo during 4 weeks in the treatment of infectious diseases induced arthritis painful symptoms. A multicenter, randomised, double-blind, placebo controlled clinical trial in adult patients suffering from Chikungunya fever
Statut
Status :
Terminé prématurément
Type d'étude
Phase III
Age Min.
18
Ans
Age Max.
-
Genre
Tous
Aire thérapeutique :
Maladie infectieuse
Maladie :
Chikungunia
Traitement :
L0013
Phase :
Phase III
Date de début de l'étude :
2006
Identifiant de l'essai :
L00013 CP 301
Identifiant EudraCT/CTIS :
2006-006165-17
Envoyer par email